SCHEMBL30786115

SCHEMBL30786115

C=Cc1ccc(C=O)cn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KCNJ1 P48048 2/20 0.40
FDPS P14324 1/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP2A6 P11509 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ALDH5A1 P51649 1/20 0.34
ABAT P80404 1/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HPGD P15428 1/20 0.34
POLB P06746 1/20 0.33
ALDH3A1 P30838 1/20 0.33
ALDH1A3 P47895 1/20 0.33
CYP11B1 P15538 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15029135 1.00 ALDH1A1 (0.40) ALDH1A1KDM4EL3MBTL1KCNJ1FDPS
SCHEMBL29440483 0.84 ALDH1A1 (0.48) ALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL5789919 0.84 ALDH1A1 (0.48) ALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL7800455 0.84 ALDH1A1 (0.43) ALDH1A1KDM4EL3MBTL1KCNJ1FDPS
SCHEMBL30895180 0.84 ALDH1A1 (0.43) ALDH1A1KDM4EL3MBTL1KCNJ1FDPS
SCHEMBL9797866 0.83 ALDH1A1 (0.42) ALDH1A1KDM4EL3MBTL1KCNJ1FDPS
SCHEMBL932015 0.77 KDM4E (0.38) KDM4EL3MBTL1
SCHEMBL22811244 0.77 MAPT (0.44) ALDH1A1KDM4EL3MBTL1KCNJ1FDPS
SCHEMBL7995673 0.74 ALDH1A1 (0.37) ALDH1A1KDM4EL3MBTL1KCNJ1FDPS
SCHEMBL30454177 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 ALDH1A1 3745/4885KDM4E 3216/4885L3MBTL1 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.